Shareholders Approve New Incentive Plan and Governance Measures
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Crispr Therapeutics AG ( (CRSP) ) has provided an update.
On June 4, 2026, CRISPR Therapeutics shareholders approved a new 2026 Stock Option and Incentive Plan that rolls over unused shares from prior equity plans and allows a broad range of stock- and cash-based awards, reinforcing the company’s ability to attract and retain key personnel. Shareholders also backed amendments to the company’s articles of association, including increases to the capital band and conditional share capital for convertible instruments, which expand CRISPR Therapeutics’ financial flexibility.
At the same Annual General Meeting, investors approved the 2025 financial statements, carried forward the net loss, discharged the Board of Directors and Executive Committee from liability, and endorsed, largely on binding terms, compensation packages and equity grants for directors and executives. The full board slate, Compensation Committee members, independent voting rights representative, and Ernst & Young as both Swiss statutory auditor and U.S. registered public accounting firm were all re-elected, signaling broad shareholder support for existing governance and leadership.
The most recent analyst rating on (CRSP) stock is a Hold
with a $56.00 price target.
To see the full list of analyst forecasts on Crispr Therapeutics AG stock,
see the CRSP Stock Forecast page.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses, negative cash flow, and volatile, partnership-driven revenue—despite a supportive equity base and improving (though still negative) cash flow. Technical indicators are neutral-to-slightly constructive, and the completed convertible notes offering improves liquidity, but negative earnings and no dividend limit valuation support.
To see Spark’s full report on CRSP stock,
click here.
More about Crispr Therapeutics AG
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9 genome editing technology. The company targets serious diseases with high unmet medical need, positioning itself within the innovative therapeutics segment of the life sciences industry and relying heavily on talent retention and equity-based incentives to support its R&D-driven strategy.
Average Trading Volume: 1,914,422
Technical Sentiment Signal: Sell
Current Market Cap: $5.02B
For a thorough assessment of CRSP stock, go to TipRanks’ Stock Analysis page.
